52 Week Range
As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay
Sept 7 (Reuters) - Biotron Ltd <BIT.AX>::ANNOUNCES CONCLUSION OF FIRST STAGE OF SCREENING SELECTED BIOTRON COMPOUNDS AGAINST SARS-COV-2.SEVERAL COMPOUNDS HAVE BEEN SHOWN IN LABORATORY CELL-CULTURE STUDIES TO HAVE ANTIVIRAL ACTIVITY AGAINST SARS- COV-2.
July 6 (Reuters) - Biotron Ltd <BIT.AX>::ADVISE THAT COMPANY IS PRESENTING NEW DATA ON ITS LEAD HIV-1 DRUG, BIT225.DATA INDICATE THAT VIA ITS INHIBITION OF HIV-1 VIRAL PROTEIN VPU, BIT225 ENHANCES IMMUNE RESPONSE TO HIV.
Nov 8 (Reuters) - Biotron Ltd <BIT.AX>::GLENEAGLE WILL UNDERWRITE ANY SHORTFALL ARISING FROM 103.1 MILLION LISTED OPTIONS EXERCISABLE AT $0.05 PER SHARE.
Oct 17 (Reuters) - Biotron Ltd <BIT.AX>::SECURES $4.7 MILLION UNDERWRITING AGREEMENT WITH CPS CAPITAL GROUP.
May 10 (Reuters) - Biotron Ltd <BIT.AX>::ANNOUNCES RENOUNCEABLE RIGHTS OFFERED AT 1.5 CENT PER SHARE TO RAISE UP TO $1.47 MILLION.
June 15 (Reuters) - Biotron Ltd <BIT.AX>:Asx alert-bit225 phase 2 hiv-1 clinical trial update-bit.ax.Trial headline results anticipated Q3 this year.Independent data and safety monitoring committee unanimously voted to proceed with second, and larger, cohort at a higher dose.
May 25 (Reuters) - Biotron Ltd <BIT.AX>:Renounceable rights offered at 2 cents per share to raise up to $1.56 million.Net proceeds will be used to complete complementary non-clinical assays on samples from current phase 2 hiv-1 clinical trial.
Biotron Limited:Issues 17,361,111 fully paid ordinary shares.
Biotron Ltd:Says that the company offers eligible shareholders opportunity to subscribe for up to $15,000 per shareholder for a total of $2.0 million of new fully paid ordinary shares in the company under share purchase plan (SPP) at a subscription price of 11.52 cents per share.Says that Patersons Securities Ltd have been mandated to complete, and have received firm commitments for, a $2.0 million placement of new shares in the company on same terms as SPP.Record date for participation in SPP is June 17.
Biotron Ltd:Announces fully underwritten renounceable rights issue to raise $4.1 million.Says net proceeds, in conjunction with existing cash reserves, will be used to complete the current Phase 2 trial that is in progress (BIT225-008 - HCV genotypes 1 and 3 trial for 3 months dosing with BIT225 in combination with IFN/RBV).
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.